Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cartesian Therapeutics (RNAC) Change in Receivables (2016 - 2025)

Cartesian Therapeutics (RNAC) has disclosed Change in Receivables for 11 consecutive years, with $393000.0 as the latest value for Q4 2025.

  • Quarterly Change in Receivables rose 109.93% to $393000.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $243000.0 through Dec 2025, up 104.86% year-over-year, with the annual reading at $243000.0 for FY2025, 104.86% up from the prior year.
  • Change in Receivables for Q4 2025 was $393000.0 at Cartesian Therapeutics, up from $368000.0 in the prior quarter.
  • The five-year high for Change in Receivables was $30.0 million in Q2 2024, with the low at -$27.2 million in Q3 2024.
  • Average Change in Receivables over 5 years is -$305450.0, with a median of -$103000.0 recorded in 2021.
  • The sharpest move saw Change in Receivables skyrocketed 13591.87% in 2022, then crashed 5487.27% in 2024.
  • Over 5 years, Change in Receivables stood at $2.6 million in 2021, then plummeted by 112.7% to -$329000.0 in 2022, then soared by 395.44% to $972000.0 in 2023, then plummeted by 507.1% to -$4.0 million in 2024, then soared by 109.93% to $393000.0 in 2025.
  • According to Business Quant data, Change in Receivables over the past three periods came in at $393000.0, $368000.0, and -$1.4 million for Q4 2025, Q3 2025, and Q2 2025 respectively.